- •Contributors of Campbell-Walsh-Wein, 12th Edition
- •Patient history and physical examination
- •Clinic visit set-up
- •Patient history
- •Chief complaint (CC)
- •History of present illness (HPI)
- •Constitutional symptoms.
- •Pain.
- •Hematuria.
- •Lower urinary tract symptoms (LUTS).
- •Urinary incontinence
- •Erectile dysfunction (ED).
- •Other urologic conditions.
- •Past medical/surgical history
- •Performance status
- •Medications
- •Social history
- •Family history
- •Review of systems
- •Physical examination
- •Vital signs
- •General appearance
- •Kidneys
- •Bladder
- •Penis
- •Scrotum and contents
- •Digital rectal examination (DRE)
- •Pelvic examination in the female
- •Laboratory tests
- •Urinalysis
- •UA evaluation
- •Specific gravity and osmolality.
- •Blood/hematuria.
- •Leukocyte esterase (LE) and nitrite.
- •Bacteria.
- •Yeast.
- •Urine cytology
- •Serum studies
- •Creatinine and glomerular filtration rate (GFR)
- •Prostate-specific antigen (PSA)
- •Alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH)
- •Endocrinologic studies
- •Parathyroid hormone
- •Office diagnostic procedures
- •Uroflowmetry
- •Post void residual (PVR)
- •Cystometography and urodynamic studies
- •Cystourethroscopy
- •Imaging of the urinary tract
- •Plain abdominal radiography.
- •Retrograde pyelogram (RPG).
- •Loopography.
- •Retrograde urethrography.
- •Voiding cystourethrogram (VCUG).
- •Functional imaging with nuclear scintigraphy
- •Technetium 99m –diethylenetriamine pentaacetic acid (99m TC-DTPA)
- •Technetium 99m –dimercaptosuccinic acid (99m TC-DMSA)
- •Technetium 99m -mercaptoacetyltriglycine (99m TC-MAG3)
- •Diuretic scintigraphy
- •Phamacokinetics.
- •Phases of dynamic renal imaging.
- •Urologic ultrasonography
- •Renal ultrasonography.
- •Bladder ultrasonography.
- •Scrotal ultrasonography.
- •Ultrasonography of the penis and male urethra.
- •Transperineal/translabial ultrasound.
- •Transrectal ultrasonography of the prostate (TRUS).
- •Urologic computed tomography (CT)
- •Types of CT.
- •Urolithiasis.
- •Cystic and solid renal masses.
- •Urologic magnetic resonance imaging (MRI)
- •Adrenal MRI.
- •Renal MRI.
- •Urothelial cell carcinoma (upper and lower tract).
- •Prostate MRI.
- •Nuclear medicine in urology
- •Positron emission tomography (PET).
- •Hematuria
- •Causes of microscopic hematuria
- •Selecting patients for evaluation
- •Lower tract evaluation
- •Upper tract evaluation
- •Suggested readings
CHAPTER 1 Evaluation of the Urologic Patient 7
Past Medical/Surgical History
It is essential to obtain a complete medical and surgical history (including prior genitourinary or abdominal surgeries). Obtain operative reports when applicable.
Performance Status
Determine the functional ability of patient as a benchmark for his or her tolerance for undergoing challenging or invasive treatments. Assess a patient’s ability to perform activities of daily living (ADLs), dressing, eating, toileting, hygiene, preparing meals, shopping, maintaining a house, and interactions with family and community. Grading performance status can be completed using the Eastern Cooperative Oncology Group (ECOG) score or Karnofsky performance status.
Medications
Obtain full medication history including urologic medications and anticoagulants. Also consider medications with urologic side effects (Table 1.2).
Social History
Review where the patient lives, who lives at home with patient, and if there are family/friends in the area. Also obtain occupational history to give insight on socioeconomic status and possible industrial exposures. Review sexual history in a non-accusatory manner such as “Do you partake in sexual relations with men, women, or both? A single partner or multiple?” Obtain drug use history including tobacco, alcohol, illicit drug use. This is important for considering withdrawal or difficulty coping during possible procedures/hospitalizations.
Family History
Ask about urologic conditions/diseases/cancers as well as bleeding disorders, reactions to anesthesia and significant non-urologic conditions/disease/cancers.
Review of Systems
Comprehensive system-based checklist related to other symptoms that may or may not be included in HPI or related to CC.
8 CHAPTER 1 Evaluation of the Urologic Patient
Table 1.2 Drugs Associated with Urologic Side Effects
UROLOGIC SIDE |
|
|
EFFECTS |
CLASS OF DRUGS |
SPECIFIC EXAMPLES |
Decreased libido |
Antihypertensives |
Hydrochlorothiazide |
Erectile dysfunction |
Psychotropic drugs |
Propranolol |
|
|
Benzodiazepines |
Ejaculatory |
a-Adrenergic |
Prazosin |
dysfunction |
antagonists |
Tamsulosin |
|
|
a-Methyldopa |
|
Psychotropic drugs |
Phenothiazines |
|
|
Antidepressants |
Priapism |
Antipsychotics |
Phenothiazines |
|
Antidepressants |
Trazodone |
|
Antihypertensives |
Hydralazine |
|
|
Prazosin |
Decreased |
Chemotherapeutic |
Alkylating agents |
spermatogenesis |
agents |
|
|
Drugs with abuse |
Marijuana |
|
potential |
Alcohol |
|
|
Nicotine |
|
Drugs affecting |
Antiandrogens |
|
endocrine function |
Prostaglandins |
Incontinence or |
Direct smooth |
Histamine |
impaired voiding |
muscle stimulants |
Vasopressin |
|
Others |
Furosemide |
|
|
Valproic acid |
|
Smooth muscle |
Diazepam |
|
relaxants |
|
|
Striated muscle |
Baclofen |
|
relaxants |
|
Urinary retention or |
Anticholinergic |
Oxybutynin |
obstructive voiding |
agents or musculo- |
Diazepam |
symptoms |
tropic relaxants |
Flavoxate |
|
Calcium channel |
Nifedipine |
|
blockers |
|
|
Antiparkinsonian |
Carbidopa |
|
drugs |
Levodopa |
|
a-Adrenergic agonists |
Pseudoephedrine |
|
|
Phenylephrine |
|
Antihistamines |
Loratadine |
|
|
Diphenhydramine |